Greenwood: A Critical Medicare Policy Has Been Delayed. Let’s Use This Opportunity to Get It Right.
BIOtech Now Andrew Segerman In a piece for Morning Consult, BIO’s Jim Greenwood writes that while CAR-T cell therapies are changing the […]
Category: News
A Sustainable Movement to Curb Cancer in Africa
BIOtech Now admin In just two years, BIO Ventures for Global Health (BVGH) has made significant progress in responding to the growing […]
New BIO White Paper: Incorporating Real-World Evidence Within the Label of an FDA-Approved Drug
BIOtech Now Sesquile Ramon In today’s increasingly connected world, health care researchers have access to previously unimaginable troves of data about the […]
The DISARM Act Can Help Fix the Broken Antibiotics Market
BIOtech Now Andrew Segerman In his a recent piece for Bloomberg, reporter Robert Langreth paints a harrowing picture of the quickly deteriorating […]
AI Helps Unravel Mystery of Neurological Disorders
BIOtech Now Jeremy Isenberg Neurological disorders are estimated to affect up to 1 billion people around the world—including nearly 100 million Americans—with […]
BIO 2019 Wraps Up in Philadelphia
BIOtech Now Theresa Brady “The world is beginning to grasp that we’ve entered the dawn of a golden age of medicine. It’s […]
U.S. as a Global Leader for Patient Access
BIOtech Now BIOtechNOW Editor Some 95 percent of cancer drugs launched around the globe are available in the U.S. Given that the […]
Opioids: Changing the Paradigm of Treating Pain and Addiction—One Year Later
BIOtech Now Jeremy Isenberg Drug overdose deaths, including those involving opioids, reached 42,000 in 2016 (CDC), prompting a national response from the […]
New Approaches to Reimbursement for Gene Therapy: What Can We Learn from Models Currently in Practice?
BIOtech Now Theresa Brady It’s obvious that cost presents a major burden for patient access to gene therapy. The recent approval of […]
BIO 2019 Innovation Zone Company Snapshot: Litron Laboratories
BIOtech Now Andrew Segerman The next big medical breakthrough is on the horizon and all it takes is one idea, one vision, […]
BIO 2019 Innovation Zone Company Snapshot: HealthRhythms, Inc.
BIOtech Now Andrew Segerman The next big medical breakthrough is on the horizon and all it takes is one idea, one vision, […]
Important Perspectives on Innovation and Costs
BIOtech Now Dan Durham This is an exciting time in biomedical innovation. New and highly innovative therapies are coming to market that […]
New BIO Report on State of Innovation for Alzheimer’s Disease Therapeutics
BIOtech Now Andrew Segerman Today, BIO released a new report: The State of Innovation in Highly Prevalent Chronic Diseases Volume IV: Alzheimer’s […]
“Health care’s big spending mismatch”
BIOtech Now Andrew Segerman This week, Axios reported on new data that shows “the health care services that rack up the highest […]
New Guide to Help Consumers Navigate Genetic Health Testing
BIOtech Now Jeremy Isenberg In recent years, we have seen a growing array of direct-to-consumer (DTC) genetic testing products rise to the […]
Promising Results Offer Hope in Fight Against Candida auris
BIOtech Now Andrew Segerman While health care conversations on Capitol Hill today are largely focused on how to best lower overall and […]
WSJ: Drug Importation is “Impractical, Unsafe and Unlikely” to Lower Prices
BIOtech Now Andrew Segerman This week, Editorial Board writers for The Wall Street Journal examined a policy proposal in Florida to import […]
Greenwood: In Pharma Value Chain, PBMs Manage to Benefit
BIOtech Now Andrew Segerman Writing for The Hill, BIO’s President and CEO Jim Greenwood offered praise to the Senate Finance Committee for calling on […]
BIO Calls Rebate Rule a “Significant Step Forward” for Patients
BIOtech Now Brian Newell The Biotechnology Innovation Organization (BIO) this week lauded an administration proposal that would be a significant step forward […]
A Few Questions as PBMs Have Their Day on Capitol Hill
BIOtech Now Brian Newell Tomorrow, the Senate Finance Committee will examine the role of pharmacy benefit managers (PBMs) in the drug cost […]